|14.11.2018||17.25||16.60||17.40||17.04||13 206 647.52|
|13.11.2018||17.50||17.20||18.33||17.25||12 847 506.75|
|12.11.2018||17.75||17.27||18.26||17.98||221 902 899.36|
|09.11.2018||18.19||17.71||18.57||17.84||220 601 981.45|
|08.11.2018||18.73||17.98||18.79||18.19||227 080 929.18|
|07.11.2018||17.70||17.54||18.67||18.66||329 909 759.87|
|06.11.2018||17.50||17.13||18.29||17.57||324 828 556.93|
|05.11.2018||18.35||17.39||18.70||18.34||412 032 246.44|
|02.11.2018||18.64||17.94||19.26||18.29||677 081 127.21|
|01.11.2018||18.00||16.91||18.87||18.76||1 696 132 292.69|
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients.
The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees.